KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Research & Development (2016 - 2025)

Resmed (RMD) has disclosed Research & Development for 17 consecutive years, with $91.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 11.79% year-over-year to $91.0 million, compared with a TTM value of $348.7 million through Dec 2025, up 9.36%, and an annual FY2025 reading of $331.3 million, up 7.73% over the prior year.
  • Research & Development was $91.0 million for Q4 2025 at Resmed, up from $87.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $91.0 million in Q4 2025 and bottomed at $55.9 million in Q1 2021.
  • Average Research & Development over 5 years is $73.7 million, with a median of $76.1 million recorded in 2023.
  • The sharpest move saw Research & Development rose 21.5% in 2023, then increased 0.83% in 2024.
  • Year by year, Research & Development stood at $62.5 million in 2021, then rose by 11.79% to $69.9 million in 2022, then rose by 5.73% to $73.9 million in 2023, then increased by 10.14% to $81.4 million in 2024, then increased by 11.79% to $91.0 million in 2025.
  • Business Quant data shows Research & Development for RMD at $91.0 million in Q4 2025, $87.3 million in Q3 2025, and $86.4 million in Q2 2025.